Solid Organ Transplant (SOT) recipients are at high risk of severe coronavirus disease-2019. Prior to the availability of vaccination, passive immunotherapies and effective antiviral therapeutics, the outcomes of COVID-19 in transplant recipients were devastating, with high morbidity and mortality.

Primary vaccination and booster programs have reduced disease severity in most populations, including SOT patients, but their immune response to vaccines is notably suboptimal.

Breakthrough COVID-19 may occur among vaccinated patients, and those with immunosuppression and high-risk comorbidities remain at increased risk of severe disease progression and death.

The administration of therapeutics, as early in the course of infection as possible, has led to reduction in severe disease progression and death among high-risk patients, including SOT recipients.

Read More